PDCD1 and neoplasm: PD-1 (programmed cell death-1) inhibitors such as nivolumab and pembrolizumab have been shown to have promising anti-tumor activity in the second-line treatment of HCC and have been approved by the FDA for HCC patients, who were previously treated with sorafenib (9, 10).